Curriculum Vitae

Ruby Gupta MD
Cleveland Clinic

10201 Carnegie avenue

Cleveland, OH, 44195

Mob: (240) 381 4733

guptar2@ccf.org
AAMC ID: 12587406

EDUCATION

MBBS (Bachelor of Medicine and Surgery)

Government Medical College, Nagpur, Maharashtra University of Health Sciences, India
Degree, MBBS: 05/ 2005

CERTIFICATIONS

ECFMG certification – 10/2007

Internal Medicine Board Certification 2014

BLS/ACLS certified

Member of American College of Physicians (Member # 01857950)

TRAINING/EXPERIENCE

Experimental Therapeutics Fellow

Cleveland Clinic 8/2018- present

Internist

Keystone Rural Health Center, Chambersburg, PA 9/2014 – 6/2018

Internal Medicine Residency:

Providence Hospital, Washington, DC 7/2011-6/2014

(George Washington University affiliate)

Psychiatry Residency PGY-I and PGY-II 7/2009 – 6/2011

Morehouse School of Medicine, Atlanta, GA

Research Assistant 01/2009- 03/2009

Spandan Heart Institute and Research center, India

Externship (Psychiatry) 2/2008 – 12/2008

Veteran Affairs Medical Center, Washington, DC

Externship (Internal Medicine) 8/2007 – 9/2007

Sky Point Medical Center, Schaumburg, Illinois

Observer (Cardiology), 7/2007 – 7/2007

Mt Sinai Medical Center, New York, NY

Spandan Heart Institute and Research center 03/2007- 06/2007

Research Assistant
Dr. H.M. Mardikar

Rural House Officer 3/2005 – 6/2007

India

Internship 01/2004 – 12/2004

Government Medical College, Nagpur, India
RESEARCH PUBLICATIONS

 Yasser Ged, Ruby Gupta, Cihan Duzgol, et al. Systemic therapy for advanced clear cell
renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF
targeted therapy combinations (IO-VEGF). J Clin Oncol 37, 2019 (suppl; abstr 4576)

 Archana Agarwal, Gregory Pond, Ruby Gupta, et al. First-line PD (L) 1 inhibitors for
platinum-ineligible advanced urothelial carcinoma (aUC). J Clin Oncol 37, 2019 (suppl;
abstr e16024)

 R Gupta, MC Ornstein, A Gul, et al. Clinical activity of ipilimumab plus nivolumab

(Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
Journal of Clinical Oncology 37 (7_suppl), 659-659 (2019)

 YW Chen, R Gupta, MC Ornstein, et al. Impact of the USPSTF recommendations on

prostate cancer stage migration and de-novo metastatic prostate cancer. Journal of
Clinical Oncology 37 (7_suppl), 166-166 (2019)

 Vadim S Koshkin, Maria C Mir, Pedro Barata, Ruby Gupta et al. Randomized Phase II
Trial of Neoadjuvant Everolimus in Patients with High-risk Localized Prostate Cancer.
Invest New Drugs. (2019)

 Pedro Barata, Cristina Magi-Galluzzi, Ruby Gupta et al. Association of mTOR Pathway
Markers and Clinical Outcomes in Patients with Intermediate/High-risk Prostate Cancer:
Long-Term Analysis. Clinical Genitourinary Cancer (2019)

 Jose Bordon, Magdalena Slomka, Ruby Gupta, et al. Hospitalization due to

Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary
Disease: Incidence, Epidemiology & Outcomes. Accepted for publication to Clinical
Microbiology and Infection.(2019)

 Pedro C. Barata1, Matthew Cooney, Prateek Mendiratta, Ruby Gupta et al. Phase I/II
Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Bevacizumab in
Patients with Chemotherapy Refractory Metastatic Castration-Resistant Prostate
Cancer. Investigational New Drugs (2018)

 R. Gupta et al. The Impact of Microsatellite stability status in colorectal cancer. Curr
Probl Cancer. 2018 Jul 18. pii: S0147-0272(17)30169-1

 Ruby Gupta, Samir Cayenne, Madhu Dyavaiah et al. Oncoyeasti: a web-based

application to translate data obtained from Saccharomyces cerevisiae high-throughput
drug screens into cancer therapeutics. F1000Research 2018, 7:757. Published June
2018

 R. Gupta, N. Anand, C. Cayenne, et al. Oncoyeasti: a web-based application to

translate data obtained from S Cervisiae high-throughput drug screens into Cancer
Therapeutics. Molecular Cancer therapeutics. 10.1158/1535-7163.TARG-17-LB-
A02 Published January 2018

 Slomka, Magdalena, Gupta Ruby, Singh Baltej et al. Streptococcus pneumoniae

Antigen, Missing Opportunities of a Promising Point of Care Diagnostic Test. Journal of
respiratory Infections. The University of Louisville Journal of Respiratory Infections. The
University of Louisville Journal of Respiratory Infections: Vol. 1 : Iss. 4 , Article 11(2017)

 Bandhary, Siddartha; Contreras-Mora, Bolivar Y., Gupta, Ruby et al. Clinical Outcomes
of Community-Acquired Pneumonia in Patients with Diabetes Mellitus. The University of
Louisville Journal of Respiratory Infections: Vol. 1 : Iss. 1 (2017)

AWARDS AND HONORS

  1st Runner up in Annual Jeopardy Competition at Washington, DC Regional ACP
meeting, May 2013

 Certified in the NIH research course – Introduction to the principles and practice of
clinical research (October 2011- March 2012)

 Preparing “ Letter of Intent “ for An open-label, single-arm, phase II trial of Lenvatinib

plus Pembrolizumab in patients with non-muscle invasive urothelial carcinoma of
bladder who are candidates for intravesical BCG therapy

POSTERS AND ABSTRACT PRESENTATIONS

 Jaleh Fallah, Ruby Gupta, Hong Li, et al. The percentage of PSA decline at 3 months in
patients with metastatic castration-sensitive prostate cancer (mCSPC) who are treated
with abiraterone/prednisone (AA/P) predicts time to development of castration-resistant
disease (mCRPC). Submitted to ESMO

 Yasser Ged, Ruby Gupta, Cihan Duzgol, et al. Systemic therapy for advanced clear cell
renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF
targeted therapy combinations (IO-VEGF). Accepted for poster presentation at ASCO
2019

 Ruby Gupta, Moshe Ornstein, Anita Gul, et al. Treatment of Metastatic Non clear cell
Renal Cell Carcinoma (nccRCC) with Ipilimumab plus Nivolumab (Ipi/Nivo). poster
presentation at GU ASCO 2019

 Yu-Wei Chen, Ruby Gupta, Moshe Ornstein, et al. Impact of the USPSTF
Recommendations on Prostate Cancer Stage Migration and De-novo Metastatic
Prostate Cancer. Poster presentation at GU ASCO 2019

 Kimberly Allman, Anita Gul, Moshe Ornstein, Ruby Gupta et al. Ipilimumab plus
Nivolumab (Ipi/Nivo) as Salvage Therapy in Patients with Immunotherapy (IO)-
Refractory Metastatic Renal Cell Carcinoma (mRCC). Oral presentation at Kidney
Cancer Association Symposium, Nov 2018

 Ruby Gupta, Nikhilesh Anand, and Samir Cayenne et al. Oncoyeasti: a web-based
application to translate data obtained from yeast high-throughput drug screens into
cancer therapeutics. Poster finalist for AACR-NCI-EORTC Molecular Targets and
Cancer Therapeutics Conference, Philadelphia, October 2017.

 Ruby Gupta, Sasan Fazeli, Manu Saini, M. Shibli. Thrombocytopenia as a Predictor of

Mortality in ICU Patients with Sepsis. First prize winner at Providence hospital and
selected as finalist for oral presentation at ACP, Washington, DC, May 2014

 Ruby Gupta, H. Sethi. Non-Small cell Lung Cancer: Brief review of diagnosis,
management and new guidelines for Lung cancer screening. Grand round, Providence
Hospital, October 2013

 Ruby Gupta, A. Singh, P M Rao and Jose Bordon. Purulent pericardial tamponade due
to MRSA after a skin and soft tissue infection. Selected as the National ACP poster
finalist presented at San Francisco, CA, April 2013

 Ruby Gupta, S. Gupta and H. Sethi. A rare case of osseous Hodgkin’s lymphoma.
Poster presented at Annual Poster Competition, Providence hospital, Washington, DC,
Feb 2013, selected as third prize winner

 Ruby Gupta, L. Miles. Metastatic pancreatic cancer presenting as acute CVA: a rare
finding. Presented at Cancer Conference, Providence Hospital, December 2012

 Ruby Gupta, Hadi Harati, Patricia Fernandez et al. Clinical Outcomes of Patients with
Diabetes Mellitus Hospitalized with Community-Acquired Pneumonia: Results from the
Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.
Poster presentation at Washington, DC regional ACP meeting, November 2012
  S. Mourad, P. Duvvuri, H. Razjouyan, R. Gupta, M. Shibli. Comparison of CAP and
HCAP with evolving adherence to ATS/IDSA guidelines: watching ourselves change.
Abstract for American Thoracic Society International Conference ajrccm-
conference.2012.185.1_MeetingAbstracts.A2573

 H.M. Mardikar, MD, N.V. Deshpande, MD, Dhananjay Deo, MD, Ruby Gupta, MD.
Optimal platelet inhibition after PCI: data from the optimal platelet inhibition with
TIrofiban and variable Clopidogrel dosing post percutaneous coronary intervention trial:
the OPTIC trial. Conference Paper in The American Journal of Cardiology. October
2007. Conference: 19th Annual Transcatheter Cardiovascular Therapeutics Symposium,
Volume: 100

Reviewer for following articles

 Manuscript ID Expert Opinion on Investigational Drugs 2018-0095: Emerging Oral

VEGF Inhibitors for the Treatment of Renal Cell Carcinoma

 Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 2017 to

present

 Translational Biomedicine 2016 to present